NAD+ Science Explained: Practitioner’s Biochemistry Guide

 

Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme for energy, repair, and cellular signalling. For clinic owners and practitioners, understanding NAD+ biochemistry supports better patient conversations, realistic expectations, and evidence-aware protocol design.

This guide offers a clear, referenced overview of the mechanism of action, core biochemical roles, age-related decline, and clinical relevance of NAD+. It’s written to be practical and non-promotional, with citations for further reading.

What is NAD+?

Definition: NAD+ is a dinucleotide coenzyme found in all living cells. It participates in hundreds of enzymatic reactions across metabolism, repair, and signalling 1.

Redox forms: The NAD+/NADH pair shuttles electrons during metabolic reactions. The ratio of NAD+ to NADH reflects cellular redox state and metabolic health 2.

NADP+/NADPH: The phosphorylated pair is central to biosynthesis and antioxidant defence 3.

Key idea: NAD+ is not just “energy related.” It’s also a substrate for DNA repair enzymes and regulators of aging pathways.

Core biochemical roles of NAD+

1) Energy production (ATP synthesis)

NAD+ accepts electrons in glycolysis and the TCA cycle, then donates them to the electron transport chain to drive ATP production. Inadequate NAD+ impairs ATP generation and cellular performance 4.

2) DNA repair and genomic stability

NAD+ is a substrate for poly(ADP-ribose) polymerases (PARPs), key enzymes that detect and repair DNA damage. Low NAD+ limits PARP activity and can compromise genome maintenance 5,6.

3) Sirtuin activation

Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate metabolism, mitochondrial function, inflammatory tone, circadian rhythms, and stem cell behaviour. Their activity closely tracks NAD+ availability 7,8.

4) Immune signalling and inflammaging

Age-related increases in CD38 (an NAD+-consuming enzyme) are linked to reduced NAD+ pools and altered immune signalling. Modulating this axis is a focus of current research 9,10.

5) Neuroprotection

NAD+ supports neuronal survival, synaptic plasticity, and resistance to excitotoxicity. Preclinical work suggests relevance in neurodegenerative settings; human studies are an active area of investigation 11,12.

Why NAD+ declines with age

  • Higher consumption: Chronic DNA damage and inflammation upregulate PARPs and CD38, which consume NAD+ 14.
  • Reduced synthesis: Enzymes involved in NAD+ biosynthesis show age-related changes 15.
  • Lifestyle stressors: Poor sleep, alcohol, ultra-processed diets, and environmental exposures can further deplete pools 16.

By midlife, tissue NAD+ levels may be 30–50% lower than in youth, with downstream effects on energy, repair, and resilience 13.

Clinical relevance: Lower NAD+ availability can present non-specifically as reduced stamina, slower recovery, or increased sensitivity to stressors — patterns common in midlife patients.

Clinical relevance for practice

Aging & longevity biology

In animal studies, restoring NAD+ improves mitochondrial function, enhances stem cell activity, and can influence healthspan markers 17. In humans, trials with NAD+ precursors such as NR and NMN show safe elevation of NAD+ in older adults, with signals in vascular and metabolic endpoints in selected cohorts 18,19,24.

Fatigue and perceived energy

Case reports and pilot studies of NAD+-based protocols (including intravenous) describe improvements in perceived energy and stamina. Mechanistically, this aligns with NAD+ roles in ATP production 20.

Neurocognitive support

Preclinical models in Parkinson’s and Alzheimer’s disease show neuroprotective signals with augmented NAD+ metabolism 21,22. Human data remain early but provide safety and pharmacokinetic insights (e.g., systemic NAD+ elevation after precursor intake) 23.

Metabolic and vascular health

Selected clinical studies report improvements in insulin sensitivity and endothelial function in middle-aged or at-risk groups following NAD+ precursor interventions 24,25.

Balanced view: While the mechanistic rationale is strong and early human findings are encouraging, large, well-controlled trials are needed across indications. Position NAD+ within comprehensive care, not as a stand-alone solution.

Delivery methods: practical overview

Note: The following is a neutral summary of commonly discussed approaches; clinics should align with local regulations and professional guidance.

Method Characteristics Considerations
Oral precursors (NR, NMN) Generally safe; raise NAD+ via conversion Efficiency varies; cohort-dependent responses 26
Intravenous NAD+ Rapid systemic availability Invasive; clinic time and cost; emerging evidence base 20
Other parenteral routes Potentially high bioavailability with minimal burden Protocols vary; ensure compliance and training

For wholesale support (training resources, logistics information, partner onboarding), see the Holte site:

Summary for practitioners

  • Centrality: NAD+ underpins energy metabolism, genome maintenance, and stress-response pathways.
  • Aging link: NAD+ availability declines with age, influenced by higher consumption (PARPs/CD38), synthesis changes, and lifestyle factors.
  • Clinical relevance: Early human studies and strong mechanistic data suggest roles in perceived energy, vascular/metabolic markers, and neurocognitive support.
  • Practical stance: Integrate NAD+-related strategies within holistic care and informed consent; monitor outcomes pragmatically.

References (Vancouver style)

  1. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death. J Biol Chem. 2008;283(10):6612–7.
  2. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12–9.
  3. Pollak N, Dölle C, Ziegler M. The power to reduce: pyridine nucleotides—small molecules with a multitude of functions. Biochem J. 2007;402:205–18.
  4. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: in vivo evidence. Cell Metab. 2018;27(3):529–47.
  5. Bai P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58(6):947–58.
  6. Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
  7. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–71.
  8. Cantó C, Auwerx J. NAD+ as a signaling molecule modulating metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:291–8.
  9. Camacho-Pereira J, Tarragó MG, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metab. 2016;23(6):1127–39.
  10. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–41.
  11. Stein LR, Imai SI. The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol Metab. 2012;23(9):420–8.
  12. Hou Y, et al. NAD+ supplementation normalizes Alzheimer’s features in a DNA-repair–deficient mouse model. Proc Natl Acad Sci U S A. 2018;115(8):E1876–85.
  13. Zhu XH, et al. In vivo NAD assay reveals intracellular NAD contents and redox state in healthy human brain and their age dependence. Proc Natl Acad Sci U S A. 2011;108(12):4866–71.
  14. Mouchiroud L, et al. The NAD+/sirtuin pathway in aging. Cell. 2013;154(4):830–48.
  15. Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear–mitochondrial communication. Cell. 2013;155(7):1624–38.
  16. Martens CR, et al. Chronic nicotinamide riboside supplementation elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
  17. Yoshino J, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–9.
  18. Airhart SE, et al. Pharmacokinetics of nicotinamide riboside in humans. PLoS One. 2017;12(12):e0186459.
  19. Schondorf DC, et al. Nicotinamide riboside rescues mitochondrial defects in Parkinson’s disease models. Cell Rep. 2018;23(10):2976–88.
  20. Martens CR, et al. Nicotinamide riboside improves vascular function in older adults. Nat Commun. 2018;9:1296.
  21. Trammell SA, Brenner C. Targeted LC-MS analysis of NAD+ metabolism. J Biol Chem. 2013;288(51):35979–90.
Back to blog